Inocras closes $31 million in Series B-3 financing to accelerate U.S. commercial expansion.
Amount Raised
$31 Million
Round Type
Series B
San DiegoBiotechnologyHealth CareGeneticsDescription
Inocras has successfully closed an oversubscribed Series B-3 financing round, raising $31 million. This funding will be utilized to support the company's commercial expansion efforts in the U.S. market. The round demonstrates strong investor confidence in Inocras's growth strategy and potential.
Who to call at Inocras & Summit Pharmaceuticals International Corporation, and when
A new round usually means Inocras & Summit Pharmaceuticals International Corporation is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Inocras & Summit Pharmaceuticals International Corporation raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Inocras & Summit Pharmaceuticals International Corporation, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Inocras & Summit Pharmaceuticals International Corporation. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Inocras & Summit Pharmaceuticals International Corporation raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansInocras & Summit Pharmaceuticals International Corporation raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.